Introduction
The substituted phenylacetyl guanidine drug guanfacine (N-amidino-2-(2,6, dichlorophenyl)-acetamide hydrochloride) has a pharmacological profile which resembles that of clonidine in some aspects (Scholtysik, Lauener, Eichenberger, Burki, Salzmann, Muller-Schweinitzer & Waite, 1975) . In v ivo the intravenous injection of guanfacine produces an initial pressor response followed by a hypotensive phase associated with depression of sympathetic outflow (Saameli, Scholtysik & Waite, 1975) but the dose levels required to produce this effect in animals and in man are at least 10 times higher than those for clonidine (Saameli et al., 1975; Waite, 1975) . This lower potency is not reflected in receptor binding assays using membranes from rat cerebral cortex, in which guanfacine is equipotent with clonidine in displacing [3H]-clonidine binding (Jarrott, Louis & Summers, 1979; Summers, Jarrott & Louis, 1980a ).
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Rebound hypertension which occurs following cessation of treatment with clonidine in man appears to be less of a problem with guanfacine (Turner, 1974; Jaattela, 1976; Kirch & Distler, 1978) . Clonidine and guanfacine have a similar powerful and selective agonist effect at prejunctional a-adrenoceptors and have been shown to reduce transmitter output from the isolated perfused heart of the rabbit (Pacha, Salzmann & Scholtysik, 1975) . However, there are indications from classical pharmacological studies (Doxey, 1979) and from receptor binding studies (Summers, Jarrott & Louis, 1980b ) that guanfacine may be more selective for 0(2-adrenoceptors than clonidine. Thus it was of interest to examine if [3H]-guanfacine at high specific activity could be used to characterize a2-adrenoceptor binding sites in membranes prepared from rat brain. 
Preparation of membranes
Rats (Sprague-Dawley 175-225 g, of either sex) were stunned, decapitated and the brains removed and placed on ice. Brain areas were dissected as described by Holman, Angwin & Barchas (1976) . Membranes for binding studies were prepared by a modification of the method of U'Prichard, Greenberg & Snyder (1977) Figure 3 . It can be seen that specific binding was saturable at ligand concentrations above 5 nM.
The effect of pH on binding was examined at a
[3H]-guanfacine concentration of -1 nM over a pH range of between 6.5 and 8.0. As can be seen from Figure 4 there was no clear pH optimum for binding. Both non-specific and total binding tended to increase with decreasing pH and so specific binding remained fairly constant. Since non-specific binding was at acceptable levels at physiological pH (7.6) this was chosen for the remaining experiments.
Saturation analysis of [3H]-guanfacine binding was
performed by addition of a buffered suspension of membranes from rat cerebral cortex to 50 mM Tris/HCl containing radioligand. Analysis of results was by an iterative least squares fitting procedure (Munson & Rodbard, 1980) . Over the range of con- adrenaline > (-)-noradrenaline > (±)-a-methylnoradrenaline > (+)-noradrenaline > methoxamine > (+)-adrenaline > phenylephrine. Antagonists also displaced binding, those which are known to have potent actions at x2-adrenoceptors being particularly effective. The rank order of potency for the antagonists was phentolamine > dihydroergocryptine > piperoxane > yohimbine > prazosin > labetalol > indoramin. The Ki values for these compounds are shown in Table 2 . A wide variety of drugs with actions predominantly on other receptor systems were also tested for their effects on [3H]-guanfacine binding. Almost all were ineffective with Ki values in excess of 10 pim. They included the jl-and f2-adrenoceptor antagonist, propranolol, the P2-adrenoceptor agonist, salbutamol and antagonists H35/25 and the Pl-adrenoceptor antagonist, metoprolol. Drugs acting on cholinoceptors including nicotine, carbachol, pempidine, atropine and (+)-tubocurarine had no effect as did the monoamine oxidase (MAO) inhibitor, pargyline, the catechol-Omethyl transferase (COMT) inhibitor, U0521, the neuronal uptake inhibitor desmethylimipramine (DMI) and the opiate antagonist, nalorphine. It was of interest to examine the effects of drugs acting on histamine receptors on [3H]-guanfacine binding since the closely related compound, clonidine, is known to stimulate a histamine-sensitive adenylate cyclase in slices of guinea-pig and rat brain. However, histamine, cimetidine, dimaprit and triprolidine had no significant effect on binding indicating that in the concentration range used, [ H]-guanfacine does not bind to histamine receptors in membranes from rat cerebral cortex. The adrenergic neurone blockers, guanethidine and debrisoquine, were also tested and found to be ineffective even though both drugs have a guanidine moiety similar to that of guanfacine. Figure 6b . Low concentrations (<10mM) of Ca2+, Mg2+, and Mn2+ produced enhancement of binding which was marked in the case of the latter two cations. High concentrations (>50mM) of all three divalent cations produced inhibition of binding.
[3H]-guanfacine binding was inhibited by guanosine 5'-triphosphate (GTP) in a concentrationdependent manner. The process was not particularly sensitive to GTP since the IC50 was 30 pM, as shown in Figure 7 .
The effects of the most potent monovalent (Na+) and divalent cations (Mn2+) and GTP were studied on the saturation of [3H]-guanfacine binding. As can be seen in Figure 8 , the major effect of Na+ (150 mM) or GTP (100 pM) was to decrease the number of sites labelled by [3H]-guanfacine. Both these compounds produced these changes with only a small decrease in apparent affinity of binding. In contrast, the divalent cation, Mn2+ (5 mM), produced a marked increase in the number of receptor sites labelled with a slight increase in apparent affinity of binding. The results of all experiments are summarized in Table 3 .
Discussion
Guanfacine (N-amidino-2-(2,6-dichlorophenyl) acetimide) is one of the most active of a new group of antihypertensive drugs, the phenylacylguanidines. Although the drug has a pharmacological profile broadly similar to that of clonidine, there are a number of important differences including a lack of effect on dopamine turnover, (Scholtysik, Jerie & Picard, 1980) central histamine H2-receptors, (Scholtysik, 1979) less central sedative effect and recently, evidence that guanfacine is more selective for a2-adrenoceptors than clonidine (Summers et al., 1980b) . These properties would be expected to make guanfacine, in tritium labelled form, a useful tool for examining M2- adrenoceptors.
[3H]-guanfacine binding met all of the criteria tested for demonstration of binding to receptors. Binding to membranes from rat cerebral cortex was linear with respect to tissue concentration up to 15 mg/ml, saturable and present in fractions enriched with plasma membranes. Total and non-specific binding were pH-dependent although specific binding was relatively little affected. The changes in binding with pH are probably dependent on changes in non-specific binding. The rank order of displacement of [3H]-guanfacine by drugs acting on aadrenoceptors indicated that, as with clonidine in rat cerebral cortex (U'Prichard et al., 1977; U'Prichard, Bechtel, Rouot & Snyder, 1979 ) guanfacine binds to a site resembling the x2-adrenoceptor. Drugs with actions on other receptor systems were largely without effect and even those which are structurally related to guanfacine such as guanethidine did not displace binding. (Scholtysik, 1980 (Kobinger, 1978) which have different efficacies in different tissues. If guanfacine has a lower efficacy in rat brain it would be expected to label more sites than clonidine. There are a number of experimental observations that support this contention. Firstly guanfacine is about 1/10th as potent as clonidine in hypertensive man and in animal models of hypertension, yet it has similar physicochemical properties and partition coefficient (Summers et al., 1980a) (Glossman & Presek, 1979; Rouot et al., 1980) . This effect is probably due to the presence of high and low affinity binding sites for
[3H]-clonidine (Rouot et al., 1980; Summers et al., 1981) ; when these are differentiated it can be seen that it is only the high affinity sites that are modulated and that the number of these sites varies with Na+, Mn2+ or GTP (Rouot et al., 1980) [3H]-clonidine.
In conclusion, [3H]-guanfacine preferentially labels a high affinity state of the cx2-adrenoceptor and this ligand may be a useful tool for examination of modulatory effects of cyclic nucleotides and ions.
